Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Rubén Pampín-Sánchez"'
Autor:
Rubén Pampín-Sánchez, Cristina Martínez-Mugica-Barbosa, Eva María Fonseca-Aizpuru, Francisco Javier Barbazán-Vázquez, Beatriz Fernández-González, Loreto Buznego-Súárez
Publikováno v:
Medicina Clínica. 160:113-117
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70024a1b6a05ac7b02abc7c697d997de
https://doi.org/10.1016/j.medcli.2022.05.007
https://doi.org/10.1016/j.medcli.2022.05.007
Autor:
Carlos Aparicio Carreño, Rubén Pampín Sánchez, Beatriz Fernández González, Cristina Martínez-Múgica Barbosa, Belén Rodríguez de Castro, Francisco Javier Barbazán Vázquez
Publikováno v:
Revista Española de Quimioterapia
espanolObjetivo. Actualmente no existe evidencia clara que guie la dosificacion de cefazolina en pacientes obesos en profilaxis quirurgica. El objetivo fue evaluar la efectividad de este antibiotico con una dosis estandar de 2 g en la prevencion de i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26ff047de8917e6ec77bf452cda556ec
https://doi.org/10.37201/req/026.2020
https://doi.org/10.37201/req/026.2020
Autor:
Teresa, Sampedro-Gimeno, Rubén, Pampín-Sánchez, Francisco Javier, Barbazán-Vázquez, Virginia, Reguero-Cuervo, Virginia, Galeazzi-Martínez, Ignacio, Pelaez-Fernández
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 45(6)
Cyclin-dependent kinase 4/6 inhibitors have a synergistic effect in combination with endocrine therapy. This combination is used as first and subsequent-line treatment for advanced luminal breast carcinoma because it increases progression-free surviv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9374cc0a77b61b3f5845f1988d8166ba
https://pubmed.ncbi.nlm.nih.gov/34806573
https://pubmed.ncbi.nlm.nih.gov/34806573
Autor:
Sonia Tembrás Martinez, Rubén Pampín Sánchez, Cristina Martínez-Múgica Barbosa, Aitor Ayastuy Ruiz, Belén Rodríguez de Castro
Publikováno v:
The International journal of risksafety in medicine. 31(4)
Background: Disease-modifying therapies for multiple sclerosis have been developed tremendously over the last two decades. Objective: The aim of this study was to review the short-, medium-, and long-term safety of alemtuzumab in relapsing remitting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39abbf02da56c675c89c4d303a899b55
https://pubmed.ncbi.nlm.nih.gov/32145001
https://pubmed.ncbi.nlm.nih.gov/32145001